{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:13:53Z","timestamp":1778260433826,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40119-023-00342-5","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T09:02:33Z","timestamp":1701853353000},"page":"233-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05210725","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Laszlo A.","family":"Groh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-9663","authenticated-orcid":false,"given":"Loes H.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Fintelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel M. P. J.","family":"Reijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloua","family":"El Messaoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel C.","family":"Warl\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,6]]},"reference":[{"issue":"1","key":"342_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","volume":"70","author":"GA Roth","year":"2017","unstructured":"Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990\u20132015. J Am Coll Cardiol. 2017;70(1):1\u201325.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"342_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","volume":"134","author":"L Kaasenbrood","year":"2016","unstructured":"Kaasenbrood L, Boekholdt SM, Graaf YVD, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016;134(19):1419\u201329.","journal-title":"Circulation"},{"issue":"14","key":"342_CR3","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"2","key":"342_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00281-017-0656-7","volume":"40","author":"L Groh","year":"2018","unstructured":"Groh L, Keating ST, Joosten LAB, Netea MG, Riksen NP. Monocyte and macrophage immunometabolism in atherosclerosis. Semin Immunopathol. 2018;40(2):203\u201314.","journal-title":"Semin Immunopathol"},{"issue":"9","key":"342_CR5","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1160\/TH16-10-0799","volume":"117","author":"D Kiers","year":"2017","unstructured":"Kiers D, van der Heijden WA, van Ede L, et al. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost. 2017;117(9):1798\u2013807.","journal-title":"Thromb Haemost"},{"issue":"4","key":"342_CR6","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/CCM.0000000000003630","volume":"47","author":"GP Leijte","year":"2019","unstructured":"Leijte GP, Kiers D, van der Heijden W, et al. Treatment with acetylsalicylic acid reverses endotoxin tolerance in humans in vivo: a randomized placebo-controlled study. Crit Care Med. 2019;47(4):508\u201316.","journal-title":"Crit Care Med"},{"issue":"6","key":"342_CR7","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1002\/jcb.28260","volume":"120","author":"L Chen","year":"2019","unstructured":"Chen L, Gao B, Zhang Y, et al. PAR2 promotes M1 macrophage polarization and inflammation via FOXO1 pathway. J Cell Biochem. 2019;120(6):9799\u2013809.","journal-title":"J Cell Biochem"},{"issue":"3","key":"342_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/cvr\/cvt343","volume":"101","author":"HMH Spronk","year":"2014","unstructured":"Spronk HMH, de Jong AM, Crijns HJ, Schotten U, Van Gelder IC, ten Cate H. Pleiotropic effects of factor\u00a0Xa and thrombin: what to expect from novel anticoagulants. Cardiovasc Res. 2014;101(3):344\u201351.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"342_CR9","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"V Aboyans","year":"2018","unstructured":"Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763\u2013816.","journal-title":"Eur Heart J"},{"key":"342_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.979819","volume":"9","author":"LH Willems","year":"2022","unstructured":"Willems LH, Thijssen DHJ, Groh LA, et al. Dual pathway inhibition as compared to acetylsalicylic acid monotherapy in relation to endothelial function in peripheral artery disease, a phase IV clinical trial. Front Cardiovasc Med. 2022;9: 979819.","journal-title":"Front Cardiovasc Med"},{"key":"342_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.atherosclerosis.2016.10.019","volume":"254","author":"S Bekkering","year":"2016","unstructured":"Bekkering S, van den Munckhof I, Nielen T, et al. Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis. 2016;254:228\u201336.","journal-title":"Atherosclerosis"},{"issue":"12","key":"342_CR12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"6","key":"342_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107615","volume":"31","author":"V Rolfes","year":"2020","unstructured":"Rolfes V, Ribeiro LS, Hawwari I, et al. Platelets fuel the inflammasome activation of innate immune cells. Cell Rep. 2020;31(6):107615.","journal-title":"Cell Rep"},{"issue":"1","key":"342_CR14","first-page":"56","volume":"38","author":"S Bose","year":"1994","unstructured":"Bose S, Roohi F, Shiralkar M. Effect of variable low doses of aspirin on platelet functions. Indian J Physiol Pharmacol. 1994;38(1):56\u201360.","journal-title":"Indian J Physiol Pharmacol"},{"issue":"3","key":"342_CR15","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000040940","volume":"101","author":"S Erhart","year":"1999","unstructured":"Erhart S, Beer JH, Reinhart WH. Influence of aspirin on platelet count and volume in humans. Acta Haematol. 1999;101(3):140\u20134.","journal-title":"Acta Haematol"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-023-00342-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-023-00342-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T19:06:36Z","timestamp":1709060796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-023-00342-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,6]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["342"],"URL":"https:\/\/doi.org\/10.1007\/s40119-023-00342-5","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,6]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Laszlo A. Groh, Loes H. Willems, Paula Fintelman, Michel M.P.J. Reijnen, Saloua El Messaoudi, and Michiel C. Warl\u00e9 have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approval of the Medical Research Ethics Committee Oost-Nederland (file number 2021-13291) and the local institutional review board was obtained. This study was conducted in accordance with the latest revision of the Helsinki Declaration of 1964 and Good Clinical Practice regulations and was registered at ClinicalTrials.gov on January\u00a027, 2022 (registration number NCT05210725). Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}